Clinical Trial Detail

NCT ID NCT02677922
Title A Safety and Efficacy Study of Oral AG-120 Plus Subcutaneous Azacitidine and Oral AG-221 Plus Subcutaneous Azacitidine in Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML)
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors Celgene
Indications

acute myeloid leukemia

myeloproliferative neoplasm

myelodysplastic syndrome

Therapies

Azacitidine + Ivosidenib

Azacitidine

Azacitidine + Enasidenib

Age Groups: senior adult

Additional content available in CKB BOOST